Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives

Tamer Nasr1, Samir Bondock2, Mahmoud Youns3

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Helwan, Egypt.

Insights

Novel coumarin derivatives combat drug-resistant cancer. Compound 7c shows potent anticancer activity by inducing apoptosis and cell cycle arrest in resistant pancreatic cancer cells, offering hope for improved patient outcomes.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Drug resistance is a significant challenge in cancer therapy.
  • Developing novel agents to overcome resistance is crucial.

Purpose of the Study:

  • To design and synthesize novel coumarin hydrazide-hydrazone derivatives.
  • To evaluate their efficacy against drug-resistant and drug-sensitive cancer cell lines.
  • To investigate their mechanism of action.

Main Methods:

  • Synthesis of sixteen coumarin hydrazide-hydrazone derivatives.
  • In vitro evaluation against human pancreatic (Panc-1), hepatic (Hep-G2), and leukemia (CCRF) cell lines.
  • Assays for cytotoxicity, caspase-3/7 activation, apoptosis induction, and gene expression (microarray).

Main Results:

  • 6-Brominated coumarin hydrazide-hydrazone derivatives (BCHHDs) 7c, 8c, and 10c demonstrated superior potency against resistant Panc-1 cells compared to doxorubicin.
  • BCHHD 7c exhibited significant cytotoxicity across all tested cell lines (IC50: 3.60–6.50 μM).
  • BCHHDs activated caspases 3/7, induced apoptosis in Panc-1 cells, and modulated key genes involved in apoptosis and cell cycle arrest (G2/M).

Conclusions:

  • BCHHD 7c is a potent anticancer agent effective against drug-resistant cancer.
  • The compound induces apoptosis and cell cycle arrest, highlighting its therapeutic potential.
  • 7c may offer a promising strategy to overcome drug resistance in clinical cancer treatment.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K